{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:26:03Z","timestamp":1782210363718,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intraperitoneal administration of BromAc (bromelain\u2009+\u2009acetylcysteine) is currently undergoing a phase 1 clinical trial for pseudomyxoma peritonei at our institution. This study reports on analysis of routine blood parameters before and after treatment for a series of 25 patients in this trial. Blood parameters assessed included full blood count, electrolytes, urea, and creatinine, liver function tests, coagulation studies, as well as inflammatory markers (CRP). Certain parameters such as CRP, and white cell count, were significantly elevated after treatment whilst serum albumin level was reduced indicating an inflammatory reaction. However, liver enzymes, coagulation studies, and other parameters were not affected. Therefore, there are no additional safety signals evident upon analysis of routine blood parameter testing.<\/jats:p>","DOI":"10.1007\/s12672-021-00418-5","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T07:04:02Z","timestamp":1629097442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study"],"prefix":"10.1007","volume":"12","author":[{"given":"Kevin","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed H.","family":"Mekkawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samina","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"issue":"1","key":"418_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1245\/s10434-020-08655-8","volume":"28","author":"T Patrick-Brown","year":"2021","unstructured":"Patrick-Brown T, et al. Estimating the prevalence of pseudomyxoma peritonei in Europe using a novel statistical method. Ann Surg Oncol. 2021;28(1):252\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"418_CR2","doi-asserted-by":"publisher","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","volume":"156","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363.","journal-title":"JAMA Surg"},{"issue":"1","key":"418_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejso.2016.08.021","volume":"43","author":"JB Delhorme","year":"2017","unstructured":"Delhorme JB, et al. Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei. Eur J Surg Oncol. 2017;43(1):159\u201367.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"418_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ejso.2014.08.476","volume":"41","author":"AC Lord","year":"2015","unstructured":"Lord AC, et al. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. Eur J Surg Oncol. 2015;41(3):396\u20139.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"418_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/bjs5.97","volume":"3","author":"F Mercier","year":"2019","unstructured":"Mercier F, et al. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. BJS Open. 2019;3(2):195\u2013202.","journal-title":"BJS Open"},{"issue":"2","key":"418_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/jso.23356","volume":"108","author":"TC Chua","year":"2013","unstructured":"Chua TC, et al. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases. J Surg Oncol. 2013;108(2):81\u20138.","journal-title":"J Surg Oncol"},{"key":"418_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.trsl.2020.10.005","volume":"229","author":"AK Dilly","year":"2021","unstructured":"Dilly AK, et al. Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer. Transl Res. 2021;229:100\u201314.","journal-title":"Transl Res"},{"key":"418_CR8","doi-asserted-by":"publisher","first-page":"976203","DOI":"10.1155\/2012\/976203","volume":"2012","author":"R Pavan","year":"2012","unstructured":"Pavan R, et al. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203.","journal-title":"Biotechnol Res Int"},{"issue":"6","key":"418_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/2042098612464265","volume":"3","author":"WS Waring","year":"2012","unstructured":"Waring WS. Novel acetylcysteine regimens for treatment of paracetamol overdose. Ther Adv Drug Saf. 2012;3(6):305\u201315.","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"418_CR10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1183\/09031936.93.02030234","volume":"2","author":"G Stafanger","year":"1989","unstructured":"Stafanger G, Koch C. N-Acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility. Eur Respir J. 1989;2(3):234\u20137.","journal-title":"Eur Respir J"},{"issue":"2","key":"418_CR11","first-page":"99","volume":"1","author":"PN Dekhuijzen","year":"2006","unstructured":"Dekhuijzen PN, van Beurden WJ. The role for N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(2):99\u2013106.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"418_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1515\/pp-2017-0013","volume":"2","author":"K Pillai","year":"2017","unstructured":"Pillai K, Akhter J, Morris DL. Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an ex vivo and in vitro study. Pleura Peritoneum. 2017;2(2):111\u20137.","journal-title":"Pleura Peritoneum"},{"issue":"1","key":"418_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejso.2019.10.033","volume":"47","author":"SJ Valle","year":"2021","unstructured":"Valle SJ, et al. A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: a phase I first in man study. Eur J Surg Oncol. 2021;47(1):115\u201322.","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"418_CR14","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1248\/cpb.34.4177","volume":"34","author":"H Hosoda","year":"1986","unstructured":"Hosoda H, et al. A comparison of chromogenic substrates for horseradish peroxidase as a label in steroid enzyme immunoassay. Chem Pharm Bull. 1986;34(10):4177\u201382.","journal-title":"Chem Pharm Bull"},{"issue":"4","key":"418_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3923\/pjn.2008.513.520","volume":"7","author":"BN Tochi","year":"2008","unstructured":"Tochi BN, et al. Therapeutic application of pineapple protease (bromelain): a review. Pak J Nutr. 2008;7(4):513\u201320.","journal-title":"Pak J Nutr"},{"issue":"4","key":"418_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1023\/A:1020563913045","volume":"19","author":"AF Suffredini","year":"1999","unstructured":"Suffredini AF, et al. New insights into the biology of the acute phase response. J Clin Immunol. 1999;19(4):203\u201314.","journal-title":"J Clin Immunol"},{"issue":"1","key":"418_CR17","doi-asserted-by":"publisher","first-page":"10566","DOI":"10.1038\/s41598-018-28646-w","volume":"8","author":"J Fest","year":"2018","unstructured":"Fest J, et al. Reference values for white blood-cell-based inflammatory markers in the Rotterdam study: a population-based prospective cohort study. Sci Rep. 2018;8(1):10566.","journal-title":"Sci Rep"},{"issue":"1","key":"418_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00152193-200501000-00014","volume":"35","author":"EL George","year":"2005","unstructured":"George EL, Panos AJN. Does a high WBC count signal infection? Nursing. 2005;35(1):20\u20131.","journal-title":"Nursing"},{"issue":"2","key":"418_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0378-8741(88)90127-4","volume":"22","author":"SJ Taussig","year":"1988","unstructured":"Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol. 1988;22(2):191\u2013203.","journal-title":"J Ethnopharmacol"},{"issue":"7","key":"418_CR20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/MBC.0000000000000244","volume":"27","author":"H Kaur","year":"2016","unstructured":"Kaur H, et al. Bromelain has paradoxical effects on blood coagulability: a study using thromboelastography. Blood Coagul Fibrinolysis. 2016;27(7):745\u201352.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"418_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijsu.2014.12.024","volume":"14","author":"A Sahbaz","year":"2015","unstructured":"Sahbaz A, et al. Bromelain: a natural proteolytic for intra-abdominal adhesion prevention. Int J Surg. 2015;14:7\u201311.","journal-title":"Int J Surg"},{"issue":"1","key":"418_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-016-2335-5","volume":"10","author":"P Forget","year":"2017","unstructured":"Forget P, et al. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes. 2017;10(1):1\u20134.","journal-title":"BMC Res Notes"},{"issue":"3","key":"418_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/hdi.12040","volume":"17","author":"K Turkmen","year":"2013","unstructured":"Turkmen K, et al. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients. Hemodial Int. 2013;17(3):391\u20136.","journal-title":"Hemodial Int"},{"issue":"2","key":"418_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jpen.1451","volume":"43","author":"PB Soeters","year":"2019","unstructured":"Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr. 2019;43(2):181\u201393.","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"1","key":"418_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/0014-5793(75)80242-0","volume":"58","author":"B Meloun","year":"1975","unstructured":"Meloun B, Moravek L, Kostka V. Complete amino acid sequence of human serum albumin. FEBS Lett. 1975;58(1):134\u20137.","journal-title":"FEBS Lett"},{"issue":"17","key":"418_CR26","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1111\/febs.14609","volume":"285","author":"A Bocedi","year":"2018","unstructured":"Bocedi A, et al. Thiol disulfide exchange reactions in human serum albumin: the apparent paradox of the redox transitions of Cys34. FEBS J. 2018;285(17):3225\u201337.","journal-title":"FEBS J"},{"issue":"1","key":"418_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2110-5820-3-4","volume":"3","author":"M Taverna","year":"2013","unstructured":"Taverna M, et al. Specific antioxidant properties of human serum albumin. Ann Intensive Care. 2013;3(1):4.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"418_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1524-475X.2004.tb00002.x","volume":"12","author":"N Kobayashi","year":"2004","unstructured":"Kobayashi N, et al. The early influence of albumin administration on protein metabolism and wound healing in burned rats. Wound Repair Regen. 2004;12(1):109\u201314.","journal-title":"Wound Repair Regen"},{"issue":"6","key":"418_CR29","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/hep.20720","volume":"41","author":"GJ Quinlan","year":"2005","unstructured":"Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41(6):1211\u20139.","journal-title":"Hepatology"},{"key":"418_CR30","doi-asserted-by":"crossref","unstructured":"Putriana L, et al. The effect of bromelain from pineapple (Ananas comosus) on increasing protein digestibility of milk replacer for lamb. In: IOP conference series: earth and environmental science. IOP Publishing; 2020.","DOI":"10.1088\/1755-1315\/478\/1\/012030"},{"issue":"7","key":"418_CR31","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/10715762.2018.1468564","volume":"52","author":"G Aldini","year":"2018","unstructured":"Aldini G, et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018;52(7):751\u201362.","journal-title":"Free Radic Res"},{"key":"418_CR32","doi-asserted-by":"publisher","first-page":"105506","DOI":"10.1016\/j.ejps.2020.105506","volume":"154","author":"S Zhang","year":"2020","unstructured":"Zhang S, et al. The enhancement of N-acetylcysteine on intestinal absorption and oral bioavailability of hydrophobic curcumin. Eur J Pharm Sci. 2020;154:105506.","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"418_CR33","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1471-4906(02)02317-7","volume":"23","author":"AA Beg","year":"2002","unstructured":"Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. 2002;23(11):509\u201312.","journal-title":"Trends Immunol"},{"issue":"10","key":"418_CR34","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/1055-9965.EPI-05-0316","volume":"14","author":"D Il'yasova","year":"2005","unstructured":"Il\u2019yasova D, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomark Prev. 2005;14(10):2413\u20138.","journal-title":"Cancer Epidemiol Biomark Prev"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-021-00418-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-021-00418-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-021-00418-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T12:16:05Z","timestamp":1673093765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-021-00418-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["418"],"URL":"https:\/\/doi.org\/10.1007\/s12672-021-00418-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"9 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DLM is the co-inventor and assignee of the Licence for this study and director of the spin-off sponsor company, Mucpharm Pty Ltd. KK, KP, AHM, JA and are employees of Mucpharm Pty Ltd. SJV is partly employed by Mucpharm for its cancer development and is supported by an Australian Government Research Training Program Scholarship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}